Spinal Stimulation + Buspirone for Paralysis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests new methods to help people with paralysis walk again. It combines noninvasive spinal stimulation with buspirone, an anti-anxiety medication, to determine if they enhance walking with devices like robotic exoskeletons and treadmills. The study includes different groups trying various methods to identify the most effective approach. It seeks participants who have had a spinal cord injury for over a year and are no longer on anti-spasticity medications. This trial may suit those who struggle with walking due to a severe spinal cord injury but have a stable condition. As an Early Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants a chance to contribute to groundbreaking advancements in spinal cord injury recovery.
Will I have to stop taking my current medications?
You may need to stop taking certain medications before joining the trial. Specifically, if you are on monoamine oxidase inhibitors, you must stop them at least 2 weeks before starting buspirone. Other medications that interact with buspirone may also need to be discontinued.
What prior data suggests that these neuromodulatory techniques are safe for people with paralysis?
Research has shown that the treatments tested in this trial have a good safety record from previous studies. The exoskeleton, a wearable robotic device, has been studied for safety and ease of use. It assists people with spinal cord injuries in walking after extensive practice, and no major safety issues have been identified.
The gravity neutral device, which simulates walking, has also been deemed safe for people with spinal cord injuries. It is used in rehabilitation, and studies have not reported any significant safety concerns.
Non-invasive spinal cord stimulation uses electrical currents to help restore movement. Research indicates it is safe and can improve movement and function in people with spinal cord injuries.
Buspirone, a medication used in the trial, is known to be safe for treating anxiety. It does not cause dependency or withdrawal problems. When studied with other drugs, it has shown no major safety issues, only mild side effects like nausea.
Overall, past research has shown these treatments to be well-tolerated, indicating they are generally safe for people with spinal cord injuries.12345Why are researchers excited about this trial's treatments?
Researchers are excited about the spinal stimulation and Buspirone combination for paralysis because it offers a novel approach compared to traditional therapies like physical rehabilitation alone. Unlike standard treatments that focus solely on physical therapy or medication, this method integrates advanced technologies such as robotic exoskeletons and gravity-neutral devices with spinal stimulation. This unique combination aims to optimize neural recovery by directly stimulating the spinal cord, potentially enhancing motor function recovery. Adding Buspirone, a medication known to impact serotonin receptors, might further boost the nervous system's responsiveness, offering a promising new avenue for people with spinal cord injuries.
What evidence suggests that this trial's treatments could be effective for paralysis?
Research has shown that robotic exoskeletons, which participants in this trial may use, can greatly improve walking in people with spinal cord injuries. One study found that training with these exoskeletons led to better mobility scores. Another group in this trial will use devices that simulate weightlessness, called gravity-neutral devices, which also appear promising as they help people with long-term paralysis control their muscles better. Non-invasive spinal cord stimulation, used across the various treatment arms in this trial, has effectively improved movement, with many participants experiencing significant benefits. The medication buspirone, which some participants may receive, has shown to aid motor function recovery when used with spinal stimulation.46789
Who Is on the Research Team?
Alexander V Ovechkin, PhD
Principal Investigator
University of Louisville
Are You a Good Fit for This Trial?
This trial is for adults aged 18-65 with stable spinal cord injuries (AIS grade A, B, or C) that occurred over a year ago. Participants must not be on anti-spasticity meds or MAO inhibitors and should have active responses in their lower spine to stimulation. Exclusions include those with certain health conditions like unhealed fractures, infections, severe diseases unrelated to the injury, pregnancy, drug abuse issues, and some medication interactions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Preparation
Participants undergo a preparation phase with up to 12 sessions in the Ekso device or gravity neutral device to determine optimal stimulation parameters
Intervention Phase 1
Participants receive training sessions 3 days/week for approximately 2 hours in the presence of stimulation and Buspirone/placebo
Intervention Phase 2
Continuation of training with the same procedures, with or without Buspirone/placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Assistive Robotic Exoskeleton
- Body Weight Supported Treadmill Training
- Buspirone
- Gravity Neutral Device
- Non-invasive Spinal Cord Stimulation
- Rolling Walker
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Louisville
Lead Sponsor
The National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator